In the phase I/II MESODEC trial (estimated study completion in 2025), vaccination with autologous DCs loaded with the mRNA encoding for the WT1 TAA (WT1/DC) has been combined with standard chemotherapy for the first-line treatment of epithelioid mesothelioma. This evidence concerns the gene WT1 and malignant epithelioid mesothelioma.